Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Praveen Mummaneni

Neurological Surgery San Francisco, CA Medical Doctor

NPI 1407960099 CMS profile 200159

400 Parnassus Ave, San Francisco, CA 94143

Open in the dashboard

General payments

$1,057,921

382 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$340,524

3 holdings reported · through program year 2025

Research they led as principal investigator

$37,500 paid to institutions, not to them · program year 2023

Through program year 2025, Praveen Mummaneni of San Francisco, CA is reported in the CMS Open Payments database as having received $1,057,921 across 382 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $37,500 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $340,524 across 3 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $65,265 81
2024 General $80,440 81
2023 General $54,484 66
2022 General $41,760 51
2021 General $112,044 28
2020 General $309,499 19
2019 General $394,430 56
2021 Ownership $113,508 1
2020 Ownership $113,508 1
2019 Ownership $113,508 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Praveen Mummaneni
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Praveen Mummaneni were reported at $65,265. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Praveen Mummaneni Neurological Surgery median Middle half National median
2019 $394,430 $582 $138–$3,006 $163
2020 $309,499 $294 $76–$2,174 $114
2021 $112,044 $387 $105–$2,432 $132
2022 $41,760 $542 $139–$2,989 $149
2023 $54,484 $534 $145–$2,697 $160
2024 $80,440 $574 $155–$3,046 $164
2025 $65,265 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. DePuy Synthes Products, Inc. $705,608 38 payments
  2. Medical Device Business Services, Inc. $127,959 43 payments
  3. Globus Medical, Inc. $123,638 117 payments
  4. NuVasive, Inc. $32,808 69 payments
  5. Medtronic, Inc. $27,584 57 payments
  6. Stryker Corporation $18,490 16 payments
  7. BK Medical Holding Company Inc. $8,613 3 payments
  8. Brainlab, Inc. $4,721 4 payments
  9. SI-BONE, Inc. $3,269 4 payments
  10. Ge Healthcare $2,600 1 payment
  11. Other $2,632 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $663,340 3 payments
  2. Consulting Fee $299,389 77 payments
  3. Travel and Lodging $47,763 137 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $34,000 10 payments
  5. Food and Beverage $12,929 154 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $500 1 payment
Products named General payments · program years 2019–2025
  1. EXPEDIUM Spine $563,577 2 payments
  2. EXPEDIUM Spine $99,864 3 payments
  3. VIPER $70,886 10 payments
  4. RELINE $44,431 42 payments
  5. ENDOSKELETON TC NANOLOCK SURFACE TECHNOLOGY $15,357 14 payments
  6. XLIF $15,106 35 payments
  7. TRITANIUM $14,762 5 payments
  8. OASYS $13,819 3 payments
  9. XIA $13,819 3 payments
  10. ES2 $13,819 3 payments
  11. Other $155,238 197 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

51

Median for Neurosurgery: 83

Drug cost

$928

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Naloxone Hcl Generic 13 $602
Baclofen Generic 16 $189
Gabapentin Generic 22 $138

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$315,012

Medicare's payments for the services billed

Medicare patients

145

Average age 73

Services billed

768

67 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 34%
Depression 34%
Osteoporosis 32%
Diabetes 30%
Chronic kidney disease 30%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

382 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record